AGM Statement

Thalia Therapeutics

30/06/2025 07:00

RNS Number : 8592O

N4 Pharma PLC

30 June 2025

 

 

30 June 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

AGM Statement

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, will hold its Annual General Meeting (AGM) at 11.00 am today at Arch Law Limited Huckletree Bishopsgate, 8 Bishopsgate, London, EC2N 4BQ.

Nigel Theobald, Chief Executive Officer, will provide the following statement:

"As outlined in the Company's final results early this month, I am pleased to report that N4 Pharma continues to deliver strong technical and operational progress, maintaining a clear strategic focus on advancing its Nuvec® RNA delivery platform.

"RNA therapeutics remains a rapidly expanding field of global interest among major pharmaceutical companies and biotech innovators, yet the central challenge persists: how to deliver these therapies safely, effectively, and intact to their target tissues. This is precisely where N4 Pharma believe Nuvec® offers a unique and highly differentiated solution.

"Over the past year, Nuvec® has generated compelling pre-clinical data, consistently meeting key performance benchmarks for next-generation RNA delivery systems. These results reinforce the Company's belief in Nuvec®'s potential to become a delivery platform of choice.

"In May 2025, building on positive data from the Company's first in vivo efficacy study of N4 101 in a standard animal model of Inflammatory Bowel Disease (IBD) and supported by a successful fundraising round in April 2025, N4 Pharma launched an expanded work programme to strengthen the commercial data package around Nuvec®.

"This enhanced programme, to be delivered over the next 12 to 18 months, is being executed by a highly experienced team with deep expertise in both science and commercialisation. It is focused on the following key data packages that are designed to support future deal-making and add significant shareholder value.

·
Oral delivery- Nuvec® protects SiRNA from degradation, which enables oral delivery to the GI tract. Oral delivery has significant advantages compared with other methods such as intrathecal injections and intravenous infusions, and, as yet, no orally delivered RNA therapeutic has been approved. N4 Pharma will expand the existing data set to demonstrate the performance of an orally delivered RNA therapeutic.
·
Endosomal release- getting the RNA into cells is one part of the process; the RNA then has to be released from the delivery vehicle for it to take effect. This is a very inefficient process with existing delivery platforms such as lipid nanoparticles, which typically release only a few per cent of the RNA. The planned work package aims to demonstrate a higher endosomal release for Nuvec® compared with lipid nanoparticles, which should lead to improved RNA delivery into the cytoplasm and increased therapeutic activity. This would be a significant competitive advantage for Nuvec® in the market.
·
Dual loading- loading of two RNA therapeutics allows delivery of two drugs in a single 'drug entity', with the potential to deliver more efficacious combination therapies, whilst only requiring a single set of toxic studies. Nuvec® is known to be able to deliver multiple RNA therapeutics, and this work programme aims to build out the existing data to demonstrate this key benefit of the Nuvec® platform.
·
CMC (Manufacturing)- it is essential that a delivery platform has class-leading performance as well as being straightforward and reproducible to manufacture. Nuvec® has been shown to be simple to manufacture, and this work package will now focus on improving yield and demonstrating sterile manufacture for human studies, which de-risks future development for a partner.
·
Targeting- the RNA to specific cell types or tissues is the holy grail of RNA therapeutics because it reduces off-target effects and improves efficacy. All RNA therapeutics developers would wish to target their drug products to specific tissues. Early work at N4 Pharma has shown that Nuvec® particles can be modified on their surface to target particular cells, and this work package will expand on this critical data set that will set Nuvec® apart from all other delivery platforms.
·
Toxicity- existing delivery platforms such as viral vectors and lipid nanoparticles have poor in vivo tolerability profiles. Nuvec® is made of silica, which is known to be benign from a toxicity perspective. This work package will demonstrate good in vivo tolerability in a number of models, which again significantly de-risks future development for a partner.
·
Pharmacokinetics and Biodistribution-it is critical that any drug gets to the site of action, remaining there long enough to have a durable effect, and that remaining drug or metabolites are excreted safely. This work package aims to measure, using standard techniques, the behaviour ofNuvec® particles in vivo to demonstrate an appropriate PK profile for RNA drugs.

"This next phase of work, building out the data packages that the Company has, is critical to achieving N4 Pharma's near-term goal: securing licensing agreements with third-party partners and enabling Nuvec® to be integrated into external RNA drug development pipelines.

"Each data package, when complete, will move N4 Pharma along the value curve, delivering increasing value to shareholders over the coming months.

"At the same time, the programme lays the foundation for the Company's longer-term ambition to develop a proprietary pipeline of RNA-based therapeutics that are both differentiated and enabled by the Nuvec® platform. These two parallel paths represent significant opportunities for near and long-term value creation.

"On behalf of the Board, I would like to thank N4 Pharma's shareholders for their continued support. Nuvec® represents a transformational opportunity for N4 Pharma, and the Company is focused on executing its strategy designed to deliver an increase in shareholder value both in the near and longer term. We look forward to providing further updates as N4 Pharma moves through this exciting and pivotal phase of development."

- Ends -

 

N4 Pharma Insight Event for Retail Investors

As announced on 25 June 2025, N4 Pharma will host an Investor Insight Event for retail investors on Monday, 14 July 2025, at the Royal College of Surgeons, 38-43 Lincoln's Inn Fields, London, WC2A 3PE, from 10.00 am until 12.00 pm. The event will include a Q&A session, offering investors the opportunity to engage directly with the executive team. This will be followed by a networking lunch, where attendees can meet other members of the Board and senior management.

 

To register for the event, please contact sarah@northstarcommunications.co.uk

 

For more information please contact:

 

N4 Pharma plc
Nigel Theobald, CEO
Luke Cairns, Executive Director
Submit your questions directly to the management team via the N4 Pharma Investor Hub
Via N4 Pharma Investor Hub:investors.n4pharma.com
https://investors.n4pharma.com/link/qy1wAr
SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
Tel: +44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited
Joint Broker
Andy Thacker
James Pope
Tel: +44 (0)20 3657 0050
Northstar Communications Limited
Investor Relations
Sarah Hollins
Tel: +44 (0)113 730 3896

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing, protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for IBD which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com or sign up at https://investors.n4pharma.com/auth/signup.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
AGMBSGDLXDDDGUC